

04-24-01
FEE TRANSMITTAL

RECEIVED

1656
B

Application Number 09/249,220
Filing Date February 12, 1999
First Named Inventor Richard A. Mueller
Attorney Docket Number SRL 6109

MAY 23 2001

RECEIVED

TECH CENTER 1600/2900

APR 30 2001

METHOD OF PAYMENT

TECH CENTER 1600/2900



- ☐ The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- ☐ The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- ☐ Applicant claims small entity status.
2. ☒ Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

FEE CALCULATION

1. ☐ BASIC FILING FEE Subtotal (1) \$ _____
(Type: _____)
2. ☐ EXTRA CLAIM FEES Subtotal (2) \$ _____
Total Claims _____
Independent Claims _____
Multiple Dependent Claims _____
3. ☒ ADDITIONAL FEES Subtotal (3) \$390.00
- ☐ Surcharge - late filing fee or oath
☐ Surcharge - late provisional filing fee or cover sheet
☒ Extension for reply within second month
☐ Notice of Appeal
☐ Filing a Brief in Support of an appeal
☐ Request for ex parte Reexamination
☐ Petitions to the Commissioner
☐ Submission of Information Disclosure Statement
☐ Recording each patent assignment per property
☐ Request for Continued Examination
☐ Other: _____

TOTAL AMOUNT OF PAYMENT \$390.00

John K. Roedel, Jr., Reg. No. 25,914

Date

JKRcwa

04/27/2001 00000034 03240220

02 FEB 2001

390.00 CP



SRL 6109 (C-3115)
PATENT

RECEIVED

APR 30 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Richard A. Mueller

Art/Unit 1656

Serial No. 09/249,220

Filed February 12, 1999

For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS FOR TREATING HEPATITIS VIRUS INFECTIONS

Examiner F. Ghashghaee

TECH CENTER 1600/2900

RECEIVED

MAY 23 2001

TECH CENTER 1600/2900

April 23, 2001

AMENDMENT A

TO THE ASSISTANT COMMISSIONER FOR PATENTS,

SIR:

In response to the Office action of November 22, 2000, the time for response to which is extended to April 22, 2001, by the attached payment of the fee required under 37 C.F.R. §1.136(a), please enter the following amendment:

IN THE CLAIMS:

Please replace claim 92 as follows:

92. (once amended) The pharmaceutical composition of claim 85, wherein said pharmaceutically acceptable salt is selected from the group consisting of acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate, and undecanoate.